DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: nab-paclitaxel

First Posted Date: 2014-03-03

Last Posted Date: 2018-10-15

Lead Sponsor: NYU Langone Health

Target Recruit Count: 3

Registration Number: NCT02075021

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography

Not Applicable

Completed

Conditions: Coronary Artery Disease
Aortic Stenosis

Interventions: Radiation: Real-time 3-dimensional DynaCT

First Posted Date: 2014-02-27

Last Posted Date: 2017-07-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 25

Registration Number: NCT02073617

Locations: 🇺🇸
NYU Langone Medical Center, New York, New York, United States

World Trade Center Adolescent Health Study

Completed

Conditions: Exposure to Toxic Dust
Asthma
Hypertension
Cardiovascular Risk Factor
Insulin Resistance
Stress Disorders, Post-Traumatic

First Posted Date: 2014-02-21

Last Posted Date: 2017-01-24

Lead Sponsor: NYU Langone Health

Target Recruit Count: 402

Registration Number: NCT02068183

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Phase 1

Terminated

Conditions: Cutaneous T-cell Lymphoma

Interventions: Drug: Romidepsin
Drug: Poly ICLC
Radiation: Focal lesional radiation

First Posted Date: 2014-02-12

Last Posted Date: 2018-12-24

Lead Sponsor: NYU Langone Health

Target Recruit Count: 3

Registration Number: NCT02061449

Locations: 🇺🇸
NYU Cancer Institute, New York, New York, United States

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Phase 2

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Diphenhydramine
Drug: Psilocybin
Behavioral: Motivational Enhancement and Taking Action (META)

First Posted Date: 2014-02-12

Last Posted Date: 2022-11-08

Lead Sponsor: NYU Langone Health

Target Recruit Count: 95

Registration Number: NCT02061293

Locations: 🇺🇸
Clinical and Translational Science Institute, NYU Langone Medical Center, New York, New York, United States
🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Functional Brain Imaging in PTSD

Completed

Conditions: Post-traumatic Stress Disorder (PTSD)
Trauma

Interventions: Procedure: Positron emission tomography/magnetic resonance imaging

First Posted Date: 2014-02-03

Last Posted Date: 2016-03-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 50

Registration Number: NCT02053532

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

DREAM Project Community Health Worker Intervention

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: CHW Intervention

First Posted Date: 2014-01-22

Last Posted Date: 2017-10-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 441

Registration Number: NCT02041598

Locations: 🇺🇸
New York University School of Medicine, Dept of Population Health, New York, New York, United States

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Device: PET/CT
Device: PET/MRI

First Posted Date: 2014-01-22

Last Posted Date: 2017-07-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT02042053

Locations: 🇺🇸
New York University Cancer Center, New York, New York, United States

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Phase 4

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: Extended-Release Naltrexone
Drug: Buprenorphine-Naloxone

First Posted Date: 2014-01-10

Last Posted Date: 2020-08-13

Lead Sponsor: NYU Langone Health

Target Recruit Count: 570

Registration Number: NCT02032433

Locations: 🇺🇸
Stanley Street Treatment and Resources, Fall River, Massachusetts, United States
🇺🇸
Avery Road Treatment Center, Rockville, Maryland, United States
🇺🇸
Tarzana Treatment Centers, Tarzana, California, United States

and more 5 locations

Biomarkers in First Episode Schizophrenia

Completed

Conditions: Schizophrenia
Schizophreniform Disorder
Schizoaffective Disorder, Depressed Type

First Posted Date: 2014-01-10

Last Posted Date: 2021-01-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 165

Registration Number: NCT02033382

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy